Literature DB >> 17356711

Estrogen and resveratrol regulate Rac and Cdc42 signaling to the actin cytoskeleton of metastatic breast cancer cells.

Nicolas G Azios1, Lakshmi Krishnamoorthy, Micheleen Harris, Luis A Cubano, Michael Cammer, Surangani F Dharmawardhane.   

Abstract

Estrogen and structurally related molecules play critical roles in breast cancer. We reported that resveratrol (50 microM), an estrogen-like phytosterol from grapes, acts in an antiestrogenic manner in breast cancer cells to reduce cell migration and to induce a global and sustained extension of actin structures called filopodia. Herein, we report that resveratrol-induced filopodia formation is time-dependent and concentration-dependent. In contrast to resveratrol at 50 microM, resveratrol at 5 microM acts in a manner similar to estrogen by increasing lamellipodia, as well as cell migration and invasion. Because Rho GTPases regulate the extension of actin structures, we investigated a role for Rac and Cdc42 in estrogen and resveratrol signaling. Our results demonstrate that 50 microM resveratrol decreases Rac and Cdc42 activity, whereas estrogen and 5 microM resveratrol increase Rac activity in breast cancer cells. MDA-MB-231 cells expressing dominant-negative Cdc42 or dominant-negative Rac retain filopodia response to 50 microM resveratrol. Lamellipodia response to 5 microM resveratrol, estrogen, or epidermal growth factor is inhibited in cells expressing dominant-negative Rac, indicating that Rac regulates estrogen and resveratrol (5 microM) signaling to the actin cytoskeleton. These results indicate that signaling to the actin cytoskeleton by low and high concentrations of resveratrol may be differentially regulated by Rac and Cdc42.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17356711      PMCID: PMC1813930          DOI: 10.1593/neo.06778

Source DB:  PubMed          Journal:  Neoplasia        ISSN: 1476-5586            Impact factor:   5.715


  49 in total

Review 1.  Integration of the extranuclear and nuclear actions of estrogen.

Authors:  Ellis R Levin
Journal:  Mol Endocrinol       Date:  2005-02-10

2.  Resveratrol and estradiol rapidly activate MAPK signaling through estrogen receptors alpha and beta in endothelial cells.

Authors:  Carolyn M Klinge; Kristy A Blankenship; Kelly E Risinger; Shephali Bhatnagar; Edouard L Noisin; Wasana K Sumanasekera; Lei Zhao; Darren M Brey; Robert S Keynton
Journal:  J Biol Chem       Date:  2004-12-22       Impact factor: 5.157

3.  Effect of resveratrol on matrix metalloproteinase-2 (MMP-2) and Secreted Protein Acidic and Rich in Cysteine (SPARC) on human cultured glioblastoma cells.

Authors:  Nicoletta Gagliano; Claudia Moscheni; Carlo Torri; Ivana Magnani; Alberto A Bertelli; Magda Gioia
Journal:  Biomed Pharmacother       Date:  2005-08       Impact factor: 6.529

4.  Inhibition of the respiratory burst by resveratrol in human monocytes: correlation with inhibition of PI3K signaling.

Authors:  Toryn M Poolman; Leong L Ng; Peter B Farmer; Margaret M Manson
Journal:  Free Radic Biol Med       Date:  2005-04-01       Impact factor: 7.376

5.  Resveratrol and estradiol exert disparate effects on cell migration, cell surface actin structures, and focal adhesion assembly in MDA-MB-231 human breast cancer cells.

Authors:  Nicolas G Azios; Suranganie F Dharmawardhane
Journal:  Neoplasia       Date:  2005-02       Impact factor: 5.715

6.  The cancer chemopreventive agent resveratrol induces tensin, a cell-matrix adhesion protein with signaling and antitumor activities.

Authors:  Christelle M Rodrigue; Françoise Porteu; Nicole Navarro; Erik Bruyneel; Marc Bracke; Paul-Henri Romeo; Christian Gespach; Marie-Claude Garel
Journal:  Oncogene       Date:  2005-05-05       Impact factor: 9.867

7.  Effect of resveratrol on the development of spontaneous mammary tumors in HER-2/neu transgenic mice.

Authors:  Mauro Provinciali; Francesca Re; Alessia Donnini; Fiorenza Orlando; Beatrice Bartozzi; Grazia Di Stasio; Arianna Smorlesi
Journal:  Int J Cancer       Date:  2005-05-20       Impact factor: 7.396

8.  Resveratrol-induced apoptosis in MCF-7 human breast cancer cells involves a caspase-independent mechanism with downregulation of Bcl-2 and NF-kappaB.

Authors:  Eulalia Pozo-Guisado; Jaime M Merino; Sonia Mulero-Navarro; M Jesús Lorenzo-Benayas; Francisco Centeno; Alberto Alvarez-Barrientos; Pedro M Fernandez-Salguero; Pedro M Fernandez Salguero
Journal:  Int J Cancer       Date:  2005-05-20       Impact factor: 7.396

9.  Atypical mechanism of regulation of the Wrch-1 Rho family small GTPase.

Authors:  Adam Shutes; Anastacia C Berzat; Adrienne D Cox; Channing J Der
Journal:  Curr Biol       Date:  2004-11-23       Impact factor: 10.834

10.  Resveratrol induces FasL-related apoptosis through Cdc42 activation of ASK1/JNK-dependent signaling pathway in human leukemia HL-60 cells.

Authors:  Jen-Liang Su; Ming-Tsan Lin; Chih-Chen Hong; Cheng-Chi Chang; Shine-Gwo Shiah; Cheng-Wen Wu; Szu-Ta Chen; Yat-Pang Chau; Min-Liang Kuo
Journal:  Carcinogenesis       Date:  2004-06-24       Impact factor: 4.944

View more
  31 in total

1.  Gene expression profiling of breast cancer cell lines in response to soy isoflavones using a pangenomic microarray approach.

Authors:  Samir Satih; Nasséra Chalabi; Nadège Rabiau; Rémy Bosviel; Luc Fontana; Yves-Jean Bignon; Dominique J Bernard-Gallon
Journal:  OMICS       Date:  2010-06

2.  Evolutionary selection of new breast cancer cell-targeting peptides and phages with the cell-targeting peptides fully displayed on the major coat and their effects on actin dynamics during cell internalization.

Authors:  Gopal Abbineni; Sita Modali; Barbara Safiejko-Mroczka; Valery A Petrenko; Chuanbin Mao
Journal:  Mol Pharm       Date:  2010-08-25       Impact factor: 4.939

3.  Ganoderma lucidum (Reishi) inhibits cancer cell growth and expression of key molecules in inflammatory breast cancer.

Authors:  Michelle M Martínez-Montemayor; Raysa Rosario Acevedo; Elisa Otero-Franqui; Luis A Cubano; Suranganie F Dharmawardhane
Journal:  Nutr Cancer       Date:  2011-09-02       Impact factor: 2.900

4.  Resveratrol, through NF-Y/p53/Sin3/HDAC1 complex phosphorylation, inhibits estrogen receptor alpha gene expression via p38MAPK/CK2 signaling in human breast cancer cells.

Authors:  Francesca De Amicis; Francesca Giordano; Adele Vivacqua; Michele Pellegrino; Maria Luisa Panno; Donatella Tramontano; Suzanne A W Fuqua; Sebastiano Andò
Journal:  FASEB J       Date:  2011-07-07       Impact factor: 5.191

5.  Dendritic cells treated with resveratrol during differentiation from monocytes gain substantial tolerogenic properties upon activation.

Authors:  Urban Svajger; Natasa Obermajer; Matjaz Jeras
Journal:  Immunology       Date:  2009-11-25       Impact factor: 7.397

6.  Inhibition of cell proliferation by a resveratrol analog in human pancreatic and breast cancer cells.

Authors:  Young Bin Hong; Hyo Jin Kang; Hee Jeong Kim; Eliot M Rosen; Sivanesan Dakshanamurthy; Riccardo Rondanin; Riccardo Baruchello; Giuseppina Grisolia; Simoni Daniele; Insoo Bae
Journal:  Exp Mol Med       Date:  2009-03-31       Impact factor: 8.718

7.  Inhibition of mammary tumor growth and metastases to bone and liver by dietary grape polyphenols.

Authors:  Linette Castillo-Pichardo; Michelle M Martínez-Montemayor; Joel E Martínez; Kristin M Wall; Luis A Cubano; Suranganie Dharmawardhane
Journal:  Clin Exp Metastasis       Date:  2009-03-18       Impact factor: 5.150

8.  The War on Cancer rages on.

Authors:  Alnawaz Rehemtulla
Journal:  Neoplasia       Date:  2009-12       Impact factor: 5.715

9.  The G protein-coupled estrogen receptor-1, GPER-1, promotes fibrillogenesis via a Shc-dependent pathway resulting in anchorage-independent growth.

Authors:  Hilary T Magruder; Jeffrey A Quinn; Jean E Schwartzbauer; Jonathan Reichner; Allan Huang; Edward J Filardo
Journal:  Horm Cancer       Date:  2014-08-06       Impact factor: 3.869

Review 10.  Multifaceted approach to resveratrol bioactivity: Focus on antioxidant action, cell signaling and safety.

Authors:  Peter Kovacic; Ratnasamy Somanathan
Journal:  Oxid Med Cell Longev       Date:  2010 Mar-Apr       Impact factor: 6.543

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.